These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 25240948)
21. [Bisphosphonate-related osteonecrosis of the jaw-after a decade has passed]. Yoneda T Clin Calcium; 2014 Mar; 24(3):407-15. PubMed ID: 24576938 [TBL] [Abstract][Full Text] [Related]
22. Treatment of bisphosphonate-related osteonecrosis of the jaw using platelet-rich fibrin. Gönen ZB; Yılmaz Asan C Cranio; 2017 Sep; 35(5):332-336. PubMed ID: 27363584 [TBL] [Abstract][Full Text] [Related]
24. Osteonecrosis of the jaw in patients treated with oral and intravenous bisphosphonates: experience in Sweden. Hallmer F; Bjørnland T; Nicklasson A; Becktor JP; Andersson G Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Aug; 118(2):202-8. PubMed ID: 25047929 [TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Vescovi P; Nammour S Minerva Stomatol; 2010 Apr; 59(4):181-203, 204-13. PubMed ID: 20360666 [TBL] [Abstract][Full Text] [Related]
26. Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report. Soydan SS; Uckan S J Oral Maxillofac Surg; 2014 Feb; 72(2):322-6. PubMed ID: 24075235 [TBL] [Abstract][Full Text] [Related]
27. Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws. Conte-Neto N; Bastos AS; Marcantonio RA; Junior EM Head Face Med; 2012 Mar; 8():5. PubMed ID: 22376948 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. El-Rabbany M; Sgro A; Lam DK; Shah PS; Azarpazhooh A J Am Dent Assoc; 2017 Aug; 148(8):584-594.e2. PubMed ID: 28527518 [TBL] [Abstract][Full Text] [Related]
29. Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases. Pelaz A; Junquera L; Gallego L; García-Consuegra L; García-Martínez L; Cutilli T; Olay S Acta Otorrinolaringol Esp; 2015; 66(3):139-47. PubMed ID: 25308796 [TBL] [Abstract][Full Text] [Related]
30. Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC). Thomas C; Spanidis M; Engel C; Roos FC; Frees S; Neisius A; Hampel C; Rubenwolf P; Thüroff JW; Walter C; Miederer M Clin Oral Investig; 2016 May; 20(4):753-8. PubMed ID: 26307268 [TBL] [Abstract][Full Text] [Related]
31. Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws. Lee LW; Hsiao SH; Chen LK J Formos Med Assoc; 2014 Mar; 113(3):166-72. PubMed ID: 24630034 [TBL] [Abstract][Full Text] [Related]
32. Management of Medication-Related Osteonecrosis of the Jaw. Williams WB; O'Ryan F Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735 [TBL] [Abstract][Full Text] [Related]
33. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. Assael LA J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813 [TBL] [Abstract][Full Text] [Related]
34. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Patel S; Choyee S; Uyanne J; Nguyen AL; Lee P; Sedghizadeh PP; Kumar SK; Lytle J; Shi S; Le AD Oral Dis; 2012 Oct; 18(7):625-32. PubMed ID: 22420684 [TBL] [Abstract][Full Text] [Related]
35. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538 [TBL] [Abstract][Full Text] [Related]
36. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? Otto S; Tröltzsch M; Jambrovic V; Panya S; Probst F; Ristow O; Ehrenfeld M; Pautke C J Craniomaxillofac Surg; 2015 Jul; 43(6):847-54. PubMed ID: 25958767 [TBL] [Abstract][Full Text] [Related]
37. [Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management]. Dupic G; Collangettes D; Dillies AF; Calvet L; Tournilhac O; Bay JO; Mahammedi H Bull Cancer; 2015 Dec; 102(12):1010-9. PubMed ID: 26607453 [TBL] [Abstract][Full Text] [Related]
38. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs. Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661 [TBL] [Abstract][Full Text] [Related]
39. The outcomes of conservative and surgical treatment of stage 2 bisphosphonate-related osteonecrosis of the jaws: a case series. Jabbour Z; El-Hakim M; Mesbah-Ardakani P; Henderson JE; Albuquerque R Int J Oral Maxillofac Surg; 2012 Nov; 41(11):1404-9. PubMed ID: 22704590 [TBL] [Abstract][Full Text] [Related]
40. Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and intravenous bisphosphonates. Shintani T; Hayashido Y; Mukasa H; Akagi E; Hoshino M; Ishida Y; Hamana T; Okamoto K; Kanda T; Koizumi K; Yoshioka Y; Tani R; Toratani S; Okamoto T Int J Oral Maxillofac Surg; 2015 Jul; 44(7):840-4. PubMed ID: 25861974 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]